Paul Hastings Advises J.P. Morgan and Oppenheimer on Lexeo Therapeutics’ Equity Financing

Paul Hastings LLP advised J.P. Morgan and Oppenheimer & Co. as co-lead placement agents in Lexeo Therapeutics’ $80 million private placement. The private placement is expected to close on May 28, 2025, subject to customary closing conditions, and proceeds will be used to fund advancement of ongoing clinical stage programs.

Chair of Equity Capital Markets and Corporate Life Sciences Seo Salimi and partner Will Magioncalda led the Paul Hastings team.

More details can be found here.

About Paul Hastings

With widely recognized elite teams across 17 practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations. For more information, visit www.paulhastings.com.